Table 1.
Baseline characteristics of subjects with HIV vs seronegative controls
| Characteristics | Controls (n=19) | PLWH (n=25) | P-value |
|---|---|---|---|
| Age (years), Mean ± SEM | 46.5 ± 2.9 | 49.6 ± 1.7 | 0.36 |
| Women, n (%) | 11 (58) | 16 (64) | 0.68 |
| BMI (kg/m2), Mean ± SEM | 25 ± 0.8 | 29 ± 1 | 0.004 |
| Diabetes, n (%) | 0 (0) | 2 (8) | 0.50 |
| HTN, n (%) | 4 (22) | 9 (36) | 0.49 |
| Smoker, n (%) | 3 (17) | 5 (20) | 0.72 |
| Statin use, n (%) | 2 (11) | 9 (36) | 0.053 |
| Years on ART, mean ± SEM | N/A | 12.6 ± 1.2 | - |
| Protease Inhibitor, n (%) | N/A | 5 (20) | - |
| NNRTI, n (%) | N/A | 4 (16) | - |
| NRTI, n (%) | N/A | 22 (88) | - |
| Integrase Inhibitor, n (%) | N/A | 21 (84) | - |
| CD4 count (mm3), mean ± SEM | N/A | 874 ± 72 | - |
| CD4 nadir (mm3), mean ± SEM | N/A | 288 ± 43 | - |
| Viral Load <20 copies/mL, n (%) | N/A | 23 (92) | - |
| Prior RVSP (mmHg), mean ± SEM | n = 15; 28.3±1.6 | - |
Abbreviations: HIV, human immunodeficiency virus; SE, standard error of the mean; BMI, body mass index; HTN, hypertension; ART, antiretroviral therapy; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; RVSP, right ventricular systolic pressure.